Member Info for Harrogate4

BV ____what do you think Avacta will be doing as a business in, say 1 year's time?

Avacta Communications Inc ( on Nasdaq)

Late RNS regarding Block listing 6 monthly return.

Why is red dot showing 4 RNSs with only 2 listed?

Nobody has heard a squeak about Darlene since her appointment to my knowledge.

What she is doing, or if she has done anything remains a complete mystery ( to SHs)

As with several other Avacta appointments.

Seems to be all part of the code of Omerta.,

B2HS2L ------"As you were."

Yes, that would make better sense and it seems he no longer works for GlycoMimetics Inc ( which is how it may appear to anyone reading their website where he still appears to be employed).

Thanks

Bella --------"Hahn is still showing on their website!!"

So do we know if Hahn works for GlycoMimetics Inc and/or Avacta or for both (or neither)

TmberTrader "Gold price in AUD, especially, "...bodes well for a good June quarter""

Nice forward guidance

thornogson ------"harrogate, what in ai's view is different from what's been said on this board fir the last 4 years?"

nothing that i can see.

it's a ****ed hat by the way.

AI's view:

Conclusions & Implications

The data from both the preclinical studies and the Phase 1 trial with AVA6000 validate the core hypothesis:

Targeted Delivery: By harnessing the tumor-specific activity of FAP, the pre|CISION® platform facilitates the concentrated release of a chemotherapeutic payload directly within the tumor, thereby maximizing local efficacy.

Enhanced Safety Profile: The improved pharmacokinetic profile (lower systemic exposure and reduced toxicities) suggests that higher effective doses can be administered safely.

Future Development: The promising clinical activity of AVA6000, combined with the robust preclinical data for AVA6103, supports further development and potential clinical testing of the exatecan payload. This could eventually widen the therapeutic window of established chemotherapeutic agents, offering a more effective and safer treatment strategy.

This poster essentially underscores the potential of a new generation of targeted anticancer therapeutics by validating a mechanism that increases drug accumulation in tumors while limiting harmful side effects systemically.

Thanks again.

Icecool,

Thanks, do you have a link please?

The embargoed Poster is due to be released in just under an hour.

Do we have any way of finding out what it was about?

BV -------" the new CEO of Avacta, Martin Branch"

When did that happen?

B2HS2L -----I accepted and sent a question! 🧐

Exactly correct, Avacta needs to get its Act together as SHs won't put up with this shabby treatment for ever.

AvctIPmatters, Yes it may be interesting.

I don't anticipate share holders here will receive any of the normal civil niceties from Avacta as to who from the company will be attending in Chicago, so was wondering if folk here have any guesses?

AvctIPmatters ------"-Poster content would be 6 pm time on Friday - Should get RNS latest Monday "

I make it 7pm on Friday 25th, but agree Monday( or Tuesday) for RNS with luck. Depends on whether embargoed Poster is Avacta's or not.

Halva -------Are you suggesting that he's now become Ice-lukewarm?

Wasn't Lukewarm in Porridge?

So one poster embargoed until 1pm on the first day of the conference---hmm, any ideas as to what that could be about?

Interesting article in today's Times by David Wighton on page 33 regarding the above.

Wonder if in some way this is contributing to the ongoing Avacta silence.

Quiet SP action today so far, or will it attack 15p towards end of play?